BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Study Shows That HyperQ Stress System From BSP - Biological Signal Processing Ltd. Can Help Detect Ischemic Heart Disease


10/19/2005 5:09:14 PM

STOCKHOLM, Sweden, September 7 /PRNewswire/ -- BSP- Biological Signal Processing Ltd. (www.bsp.co.il) announced today the presentation of results from a large-scale clinical study of its HyperQ(TM) Stress System at the 2005 European Society of Cardiology Congress. The encouraging results provide positive scientific evidence that stress-induced ischemia could be accurately detected using the HyperQ(TM) Stress System. The system uses sophosticated analysis of the ECG signal to provide a reliable measure for cardiac ischemia, based on the high-frequency components of the ECG. The HyperQ(TM) Stress system, cleared for sale by the FDA and carries the CE mark, is the first commercially available device that allows high-frequency mid-QRS analysis in addition to conventional stress ECG, offering an accurate and effective noninvasive tool for the detection of ischemic heart disease.

The presented study assessed the diagnostic efficacy of the HyperQ(TM) Stress System in detecting exercise-induced ischemia in 900 patients referred for SPECT myocardial perfusion imaging (nuclear mapping of the cardiac muscle). Results indicated that the HyperQ(TM) analysis significantly improved the diagnostic ability of the Stress Test, reaching impressive sensitivity of 78% and specificity of 86%.

"We have successfully demonstrated that the HyperQ(TM) system offers a superior tool for Ischemia detection, without any modifications to the traditional stress test protocol" said Dr. Haim Silber, who was the principal investigator in the study and who presented it at the conference.

The High Frequency QRS analysis is an innovative method for noninvasive diagnosis of Myocardial Ischemia. "The technology developed by BSP to extract the HyperQ(TM) Signal can be integrated within a wide range of clinical systems, offering unmatched detection capabilities for ischemic conditions", said Dr. Amir Beker, BSP's founder and CEO.

BSP has been awarded a grant by the Office of the Chief Scientist (OCS) of Israel's Ministry of Industry and Trade for supporting a NIS 1.7 million R&D budget. The funds have been granted for the development of BSP's next application, the HyperQ Rest Monitor.

BSP was founded in 2000, consisting of top signal processing experts, biomedical engineers and clinicians. BSP's chief scientist is Prof. Shimon Abboud, a pioneering researcher in the field of high-frequency ECG and a world leader in ECG signal analysis for more than 25 years.

Contact: Amir Beker, CEO amir@bsp.co.il Tel. +972-3-6474840

BSP - Biological Signal Processing Ltd

CONTACT: Contact: Amir Beker, CEO, amir@bsp.co.il, Tel. +972-3-6474840



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES